Biodesix to present new real-world data on Nodify Lung testing at ATS 2026, highlighting clinical and economic benefits.

Biodesix, a diagnostics company, announced it will share new real-world clinical and economic data on its Nodify Lung blood-based test at the American Thoracic Society (ATS) Annual Meeting in May 2026. The data supports the test's role in earlier lung cancer detection and improved patient care, with presentations from leading medical centers and community hospitals. This highlights growing adoption and the test's value in lung nodule risk assessment and management. Attendees can find Biodesix at booth #1327 during the conference.